SI1010693T1 - Imidazoline derivatives, preparation and pharmaceutical compositions containing them - Google Patents

Imidazoline derivatives, preparation and pharmaceutical compositions containing them

Info

Publication number
SI1010693T1
SI1010693T1 SI9930414T SI9930414T SI1010693T1 SI 1010693 T1 SI1010693 T1 SI 1010693T1 SI 9930414 T SI9930414 T SI 9930414T SI 9930414 T SI9930414 T SI 9930414T SI 1010693 T1 SI1010693 T1 SI 1010693T1
Authority
SI
Slovenia
Prior art keywords
alkyl
imidazoline derivatives
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
SI9930414T
Other languages
English (en)
Slovenian (sl)
Inventor
Alex Cordi
Jean-Michel Lacoste
Mark Millan
Adrian Newman-Tancredi
Alain Gobert
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of SI1010693T1 publication Critical patent/SI1010693T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9930414T 1998-12-18 1999-12-17 Imidazoline derivatives, preparation and pharmaceutical compositions containing them SI1010693T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815999A FR2787451B1 (fr) 1998-12-18 1998-12-18 Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP99403190A EP1010693B1 (fr) 1998-12-18 1999-12-17 Nouveaux composés imidazoliniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
SI1010693T1 true SI1010693T1 (en) 2004-02-29

Family

ID=9534132

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930414T SI1010693T1 (en) 1998-12-18 1999-12-17 Imidazoline derivatives, preparation and pharmaceutical compositions containing them

Country Status (22)

Country Link
US (1) US6127396A (pt)
EP (1) EP1010693B1 (pt)
JP (1) JP3526800B2 (pt)
KR (1) KR100492160B1 (pt)
CN (1) CN1183907C (pt)
AT (1) ATE250586T1 (pt)
AU (1) AU767856B2 (pt)
BR (1) BR9907497A (pt)
CA (1) CA2292927C (pt)
DE (1) DE69911557T2 (pt)
DK (1) DK1010693T3 (pt)
EA (1) EA004536B1 (pt)
ES (1) ES2209362T3 (pt)
FR (1) FR2787451B1 (pt)
HK (1) HK1027573A1 (pt)
HU (1) HUP9904628A3 (pt)
NO (1) NO314544B1 (pt)
NZ (1) NZ501785A (pt)
PL (1) PL202198B1 (pt)
PT (1) PT1010693E (pt)
SI (1) SI1010693T1 (pt)
ZA (1) ZA997734B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
EP1028110B1 (en) * 1997-10-02 2004-04-14 Daiichi Pharmaceutical Co., Ltd. Novel dihydronaphthalene compounds and process for producing the same
US6559157B2 (en) 1997-10-02 2003-05-06 Daiichi Pharmaceutical Co., Ltd. Dihydronaphthalene compounds
DE60121986T2 (de) * 2000-10-02 2007-07-26 Emory University Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
MX2007007103A (es) * 2004-12-13 2008-03-10 Lilly Co Eli Derivados espiro como inhibidores de lipoxigenasa.
CA2691704A1 (en) * 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
WO2009089285A2 (en) * 2008-01-07 2009-07-16 Emory University Branched diepoxide compounds for the treatment of inflammatory disorders
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
US8771391B2 (en) 2011-02-22 2014-07-08 Baker Hughes Incorporated Methods of forming polycrystalline compacts
JP6692162B2 (ja) * 2014-01-17 2020-05-13 キッセイ薬品工業株式会社 α−置換グリシンアミド誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE23337T1 (de) * 1982-12-23 1986-11-15 Ici America Inc Chromanverbindungen.
US4540705A (en) * 1983-03-14 1985-09-10 Sterling Drug Inc. Antidepressant imidazolines and related compounds
FR2542738A1 (fr) * 1983-03-18 1984-09-21 Synthelabo Indanyl-2 d2-imidazoline, procede pour la preparer, et compositions pharmaceutiques qui la contiennent
EP0166937B1 (en) * 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
JPH01242571A (ja) * 1988-03-22 1989-09-27 Mitsui Petrochem Ind Ltd イミダゾール誘導体の製造方法
US5151526A (en) * 1990-10-11 1992-09-29 The United States Of America As Represented By The Secretary Of The Army 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic
KR920008026A (ko) * 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
AU5118493A (en) * 1992-10-06 1994-04-26 Tokyo Tanabe Company Limited Aromatase inhibitor
DE19605400A1 (de) * 1996-02-14 1997-08-21 Bayer Ag Salze von Imidazolin-Derivaten
FR2756560A1 (fr) * 1996-12-04 1998-06-05 Adir Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CN1183907C (zh) 2005-01-12
AU767856B2 (en) 2003-11-27
HUP9904628A3 (en) 2001-02-28
CA2292927C (fr) 2005-09-13
NO314544B1 (no) 2003-04-07
FR2787451B1 (fr) 2001-01-26
NO996284D0 (no) 1999-12-17
EA004536B1 (ru) 2004-06-24
DK1010693T3 (da) 2004-02-09
PL202198B1 (pl) 2009-06-30
CN1257864A (zh) 2000-06-28
DE69911557T2 (de) 2004-06-17
EP1010693B1 (fr) 2003-09-24
HUP9904628A2 (hu) 2000-08-28
PL337196A1 (en) 2000-06-19
EP1010693A1 (fr) 2000-06-21
JP3526800B2 (ja) 2004-05-17
US6127396A (en) 2000-10-03
ES2209362T3 (es) 2004-06-16
KR100492160B1 (ko) 2005-06-02
FR2787451A1 (fr) 2000-06-23
NO996284L (no) 2000-06-19
AU6529099A (en) 2000-06-22
NZ501785A (en) 2001-01-26
EA199901050A2 (ru) 2000-06-26
BR9907497A (pt) 2000-09-26
HK1027573A1 (en) 2001-01-19
JP2000178255A (ja) 2000-06-27
HU9904628D0 (en) 2000-02-28
DE69911557D1 (de) 2003-10-30
ZA997734B (en) 2000-06-29
CA2292927A1 (fr) 2000-06-18
PT1010693E (pt) 2003-12-31
EA199901050A3 (ru) 2000-10-30
KR20000052509A (ko) 2000-08-25
ATE250586T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
IL114894A (en) Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments
EP0902007A4 (en) CHALCON DERIVATIVES AND MEDICINES THAT CONTAIN THEM
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
SI1010693T1 (en) Imidazoline derivatives, preparation and pharmaceutical compositions containing them
CA2119662A1 (fr) Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL106445A0 (en) 4-substituted 1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
IL125982A0 (en) 2-(arylphenyl) amino-imidazoline derivatives
IL90424A (en) Cephem derivatives, processes for the preparation thereof and pharmaceutical composition containing the same
CZ125895A3 (en) The use of dimethylbenzofuran and dimethylbenzopyran derivatives as 5-ht3antagonists, novel dimethylbenzofuran and dimethylbenzopyran derivatives, intermediates for preparing thereof and pharmaceutical preparations
AU631262B2 (en) Nmda-blocking pharmaceutical compositions
EA199901049A3 (ru) Спироимидазолиновые соединения, способ их получения и фармацевтическая композиция, содержащая их
HUT76480A (en) Alkyl-5-methyl-sulphonyl-benzoyl-guanidine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
GR3007498T3 (pt)
FI970452A (fi) Leukotrieenin biosynteesin estäminen ureajohdannaisten avulla
AU653019B2 (en) New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
HUT65376A (en) Process for preparing n,n',n-trisubstituted 5-(diamino-methylene)-1,3-dioxane-4,6-diones and pharmaceutical compositions containing them as active ingredient